Global Biopharmaceutical Market Report & Forecast (2012-2017)

Published by: IMARC

Published: Sep. 27, 2012 - 238 Pages


Table of Contents

1. Market Definitions & Research Methodology
2. Analyst Briefing
3. Introduction to Biopharmaceuticals
4. Global Biopharmaceutical Market: Industry Analysis
4.1 Strengths
4.1.1 High Efficacy and Target Oriented Attack
4.1.2 Strong Potential to Achieve Blockbuster Status
4.1.3 Limited Generic Threat
4.1.4 Approval Success Rates are Higher than Small Molecule Drugs
4.2 Weaknesses
4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives
4.2.2 Second Line of Therapy
4.2.3 Huge Cost of Therapy
4.2.4 High Incidence of Unfavorable Side Effects
4.3 Opportunities
4.3.1 Diseases with High Unmet Needs
4.3.2 Expanding the Patient Pool by Approval into Additional Indications
4.3.3 Emerging Markets
4.3.4 Increasing New Approvals and a Strong Pipeline
4.4 Threats
4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
4.4.2 Biosimilars
4.4.3 Limited and Conditional Reimbursement
4.4.4 Uncertainties in the Economic Environment
5. Global Biopharmaceutical Market: Industry Performance
5.1 Market Performance & Forecast
5.1.1 Current Performance (2005-2011)
5.1.2 Market Forecast (2012-2017)
5.2 Market Segmentation by Region
5.2.1 Current Performance (2005-2011)
5.2.2 Market Forecast (2012-2017)
5.3 Market Segmentation by Indication
5.4 Market Segmentation by Class
5.4.1 Recombinant Proteins
5.4.1.1 Current Performance (2005-2011)
5.4.1.2 Market Forecast (2012-2017)
5.4.2 Monoclonal Antibodies
5.4.2.1 Current Performance (2005-2011)
5.4.2.2 Market Forecast (2012-2017)
5.4.3 Purified Proteins
5.4.3.1 Current Performance (2005-2011)
5.4.3.2 Market Forecast (2012-2017)
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs
6. North America
6.1 US
6.1.1 Market Performance (2005-2011)
6.1.2 Market Segmentation by Class
6.1.2.1 Recombinant Proteins
6.1.2.2 Monoclonal Antibodies
6.1.2.3 Purified Proteins
6.1.3 Performance of Top Players
6.1.4 Market Forecast (2012-2017)
6.2 Canada
6.2.1 Market Performance (2005-2011)
6.2.2 Market Segmentation by Class
6.2.2.1 Recombinant Proteins
6.2.2.2 Monoclonal Antibodies
6.2.3 Performance of Top Players
6.2.4 Market Forecast (2012-2017)
7. Latin America
7.1 Mexico
7.1.1 Market Performance (2005-2011)
7.1.2 Market Segmentation by Class
7.1.2.1 Recombinant Proteins
7.1.2.2 Monoclonal Antibodies
7.1.2.3 Purified Proteins
7.1.3 Performance of Top Players
7.1.4 Market Forecast (2012-2017)
7.2 Brazil
7.2.1 Market Performance (2005-2011)
7.2.2 Market Segmentation by Class
7.2.2.1 Recombinant Proteins
7.2.2.2 Monoclonal Antibodies
7.2.2.3 Purified Proteins
7.2.3 Performance of Top Players
7.2.4 Market Forecast (2012-2017)
7.3 Argentina
7.3.1 Market Performance (2005-2011)
7.3.2 Market Segmentation by Class
7.3.2.1 Recombinant Proteins
7.3.2.2 Monoclonal Antibodies
7.3.2.3 Purified Proteins
7.3.3 Performance of Top Players
7.3.4 Market Forecast (2012-2017)
8. Europe
8.1 Germany
8.1.1 Market Performance (2005-2011)
8.1.2 Market Segmentation by Class
8.1.2.1 Recombinant Proteins
8.1.2.2 Monoclonal Antibodies
8.1.2.3 Purified Proteins
8.1.3 Performance of Top Players
8.1.4 Market Forecast (2012-2017)
8.2 France
8.2.1 Market Performance (2005-2011)
8.2.2 Market Segmentation by Class
8.2.2.1 Recombinant Proteins
8.2.2.2 Monoclonal Antibodies
8.2.2.3 Purified Proteins
8.2.3 Performance of Top Players
8.2.4 Market Forecast (2012-2017)
8.3 Italy
8.3.1 Market Performance (2005-2011)
8.3.2 Market Segmentation by Class
8.3.2.1 Recombinant Proteins
8.3.2.2 Monoclonal Antibodies
8.3.2.3 Purified Proteins
8.3.3 Performance of Top Players
8.3.4 Market Forecast (2012-2017)
8.4 Spain
8.4.1 Market Performance (2005-2011)
8.4.2 Market Segmentation by Class
8.4.2.1 Recombinant Proteins
8.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
8.4.3 Performance of Top Players
8.4.4 Market Forecast (2012-2017)
8.5 UK
8.5.1 Market Performance (2005-2011)
8.5.2 Market Segmentation by Class
8.5.2.1 Recombinant Proteins
8.5.2.2 Monoclonal Antibodies
8.5.2.3 Purified Proteins
8.5.3 Performance of Top Players
8.5.4 Market Forecast (2012-2017)
8.6 Russia
8.6.1 Market Performance (2005-2011)
8.6.2 Market Segmentation by Class
8.6.2.1 Recombinant Proteins
8.6.2.2 Monoclonal Antibodies
8.6.2.3 Purified Proteins
8.6.3 Performance of Top Players
8.6.4 Market Forecast (2012-2017)
8.7 Turkey
8.7.1 Market Performance (2005-2011)
8.7.2 Market Segmentation by Class
8.7.2.1 Recombinant Proteins
8.7.2.2 Monoclonal Antibodies
8.7.2.3 Purified Proteins
8.7.3 Performance of Top Players
8.7.4 Market Forecast (2012-2017)
9. Asia Pacific
9.1 Japan
9.1.1 Market Performance (2005-2011)
9.1.2 Market Segmentation by Class
9.1.2.1 Recombinant Proteins
9.1.2.2 Monoclonal Antibodies
9.1.2.3 Purified Proteins
9.1.3 Performance of Top Players
9.1.4 Market Forecast (2012-2017)
9.2 China
9.2.1 Market Performance (2005-2011)
9.2.2 Market Segmentation by Class
9.2.2.1 Recombinant Proteins
9.2.2.2 Monoclonal Antibodies
9.2.2.3 Purified Proteins
9.2.3 Performance of Top Players
9.2.4 Market Forecast (2012-2017)
9.3 Australia
9.3.1 Market Performance (2005-2011)
9.3.2 Market Segmentation by Class
9.3.2.1 Recombinant Proteins
9.3.2.2 Monoclonal Antibodies
9.3.2.3 Purified Proteins
9.3.3 Performance of Top Players
9.3.4 Market Forecast (2012-2017)
9.4 South Korea
9.4.1 Market Performance (2005-2011)
9.4.2 Market Segmentation by Class
9.4.2.1 Recombinant Proteins
9.4.2.2 Monoclonal Antibodies
9.4.2.3 Purified Proteins
9.4.3 Performance of Top Players
9.4.4 Market Forecast (2012-2017)
9.6 India
9.6.1 Market Performance (2005-2011)
9.6.2 Market Segmentation by Class
9.6.2.1 Recombinant Proteins
9.6.2.2 Monoclonal Antibodies
9.6.2.3 Purified Proteins
9.6.3 Performance of Top Players
9.6.4 Market Forecast (2012-2017)
9.7 Indonesia
9.7.1 Market Performance (2005-2011)
9.7.2 Market Segmentation by Class
9.7.2.1 Recombinant Proteins
9.7.2.2 Monoclonal Antibodies
9.7.3 Performance of Top Players
9.7.4 Market Forecast (2012-2017)
List of Figures
Figure 2 1: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 3 1: Complexity of Biopharmaceuticals
Figure 3 2: Sources of Biopharmaceuticals
Figure 4 1: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2000, 2011 & 2016
Figure 4 2: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
Figure 4 3: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
Figure 4 4: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
Figure 4 5: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 4 6: Comparison of the Annual Cost of Therapy for Plaque Psoriasis Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 4 7: Emerging Biopharmaceutical Market Forecast (in Million US$), 2011 & 2017
Figure 4 8: Developed Biopharmaceutical Market Forecast (in Million US$), 2011 & 2017
Figure 4 9: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 1997 - 2011
Figure 4 10: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in %), 1997 - 2011
Figure 4 11: Global: Breakup of Small Molecule Drugs and Biopharmaceuticals in the Total Pharmaceutical Market & Phase III development (%), 2011
Figure 4 12: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
Figure 4 13: Research and Development Times Taken by Biopharmaceuticals to Reach the Market (in Months), 1982-89,1990-94,1995-99, 2000-04, 2005-09
Figure 4 14: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)
Figure 4 15: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2011
Figure 4 16: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2011
Figure 4 17: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2011
Figure 4 18: Current Medicare Payer Coverage for Monoclonal Antibodies
Figure 4 19: Performance of Biotech Stocks During the Financial Crisis (in %), Jan 2008 to Dec 2008
Figure 5 1: Global: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 5 2: Global: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 5 3: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2011
Figure 5 4: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2017
Figure 5 5: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2011
Figure 5 6: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 5 7: Global: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 5 8: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2012-2017
Figure 5 9: Global: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2012-2017
Figure 5 10: Global: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 5 11: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 5 12: Global: Recombinant Proteins Market Forecast (in Million US$), 2012-2017
Figure 5 13: Global: Recombinant Proteins Market Forecast: Sales Share by Class (in %), 2017
Figure 5 14: Global: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 5 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 5 16: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2012-2017
Figure 5 17: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class (in %), 2017
Figure 5 18: Global: Purified Proteins Market (in Million US$), 2005-2011
Figure 5 19: Global: Purified Proteins Market: Sales Share by Class (in %), 2011
Figure 5 20: Global: Purified Proteins Market Forecast (in Million US$), 2012-2017
Figure 5 21: Global: Purified Proteins Market Forecast: Sales Share by Class (in %), 2017
Figure 5 22: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 6 1: US: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 6 2: US: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 6 3: US: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 6 4: US: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 6 5: US: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 6 6: US: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 6 7: US: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 6 8: US: Purified Proteins Market (in Million US$), 2005-2011
Figure 6 9: US: Purified Proteins Market: Sales Share by Class (in %), 2011
Figure 6 10: US: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 6 11: US: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 6 12: US: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 6 13: Canada: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 6 14: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 6 15: Canada: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 6 16: Canada: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 6 17: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 6 18: Canada: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 6 19: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 6 20: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 6 21: Canada: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 6 22: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 7 1: Mexico: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 7 2: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 7 3: Mexico: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 7 4: Mexico: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 7 5: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 7 6: Mexico: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 7 7: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 7 8: Mexico: Purified Proteins Market (in Million US$), 2005-2011
Figure 7 9: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 7 10: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 7 11: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 7 12: Brazil: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 7 13: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 7 14: Brazil: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 7 15: Brazil: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 7 16: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 7 17: Brazil: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 7 18: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 7 19: Brazil: Purified Proteins Market (in Million US$), 2005-2011
Figure 7 20: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 7 21: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 7 22: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 7 23: Argentina: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 7 24: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 7 25: Argentina: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 7 26: Argentina: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 7 27: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 7 28: Argentina: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 7 29: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 7 30: Argentina: Purified Proteins Market (in Million US$), 2005-2011
Figure 7 31: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 7 32: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 7 33: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 8 1: Germany: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 8 2: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 8 3: Germany: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 8 4: Germany: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 8 5: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 8 6: Germany: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 8 7: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 8 8: Germany: Purified Proteins Market (in Million US$), 2005-2011
Figure 8 9: Germany: Purified Proteins Market: Sales Share by Class (in %), 2011
Figure 8 10: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 8 11: Germany: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 8 12: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 8 13: France: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 8 14: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 8 15: France: Biopharmaceutical Market: Sales Share By Class (in %), 2005-2011
Figure 8 16: France: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 8 17: France: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 8 18: France: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 8 19: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 8 20: France: Purified Proteins Market (in Million US$), 2005-2011
Figure 8 21: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 8 22: France: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 8 23: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 8 24: Italy: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 8 25: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 8 26: Italy: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 8 27: Italy: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 8 28: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 8 29: Italy: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 8 30: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 8 31: Italy: Purified Proteins Market (in Million US$), 2005-2011
Figure 8 32: Italy: Biopharmaceutical Market: Sales Share of top players (in %), 2011
Figure 8 33: Italy: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 8 34: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 8 35: Spain: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 8 36: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 8 37: Spain: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 8 38: Spain: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 8 39: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 8 40: Spain: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 8 41: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 8 42: Spain: Purified Proteins Market (in Million US$), 2005-2011
Figure 8 43: Spain: Purified Proteins Market: Sales Share by Class (in %), 2011
Figure 8 44: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 8 45: Spain: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 8 46: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 8 47: UK: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 8 48: UK: Biopharmaceutical Market, Sales by Class (in Million US$), 2005-2011
Figure 8 49: UK: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 8 50: UK: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 8 51: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 8 52: UK: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 8 53: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 8 54: UK: Purified Proteins Market (in Million US$), 2005-2011
Figure 8 55: UK: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 8 56: UK: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 8 57: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 8 58: Russia: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 8 59: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 8 60: Russia: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 8 61: Russia: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 8 62: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 8 63: Russia: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 8 64: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 8 65: Russia: Purified Proteins Market (in Million US$), 2005-2011
Figure 8 66: Russia: Purified Proteins Market: Sales Share by Class (in %), 2011
Figure 8 67: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 8 68: Russia: Biopharmaceutical Market Forecast (in Million US$), 2011-2017
Figure 8 69: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 8 70: Turkey: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 8 71: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 8 72: Turkey: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 8 73: Turkey: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 8 74: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 8 75: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 8 76: Turkey: Purified Proteins Market (in Million US$), 2005-2011
Figure 8 77: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 8 78: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 8 79: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 9 1: Japan: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 9 2: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 9 3: Japan: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 9 4: Japan: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 9 5: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 9 6: Japan: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 9 7: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 9 8: Japan: Purified Proteins Market (in Million US$), 2005-2011
Figure 9 9: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 9 10: Japan: Biopharmaceutical Market Forecast (in Million US$), 2012 - 2017
Figure 9 11: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 9 12: China: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 9 13: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 9 14: China: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 9 15: China: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 9 16: China: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 9 17: China: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 9 18: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 9 19: China: Purified Proteins Market (in Million US$), 2005-2011
Figure 9 20: China: Purified Proteins Market: Sales Share by Class (in %), 2011
Figure 9 21: China: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 9 22: China: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 9 23: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 9 24: Australia: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 9 25: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 9 26: Australia: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 9 27: Australia: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 9 28: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 9 29: Australia: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 9 30: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 9 31: Australia: Purified Proteins Market (in Million US$), 2005-2011
Figure 9 32: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 9 33: Australia: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 9 34: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 9 35: South Korea: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 9 36: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 9 37: South Korea: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 9 38: South Korea: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 9 39: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 9 40: South Korea: Monoclonal Antibodies Market (in Million US$), 2005 - 2011
Figure 9 41: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2011
Figure 9 42: South Korea: Purified Proteins Market (in Million US$), 2005-2011
Figure 9 43: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2011
Figure 9 44: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 9 45: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 9 46: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 9 47: India: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 9 48: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 9 49: India: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 9 50: India: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 9 51: India: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 9 52: India: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 9 53: India: Purified Proteins Market (in Million US$), 2005-2011
Figure 9 54: India: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 9 55: India: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 9 56: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
Figure 9 57: Indonesia: Biopharmaceutical Market (in Million US$), 2005-2011
Figure 9 58: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2005-2011
Figure 9 59: Indonesia: Biopharmaceutical Market: Sales Share by Class (in %), 2005-2011
Figure 9 60: Indonesia: Recombinant Proteins Market (in Million US$), 2005-2011
Figure 9 61: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2011
Figure 9 62: Indonesia: Monoclonal Antibodies Market (in Million US$), 2005-2011
Figure 9 63: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2011
Figure 9 64: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2011
Figure 9 65: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2012-2017
Figure 9 66: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2017
List of Tables
Table 1 1: Global: Biopharmaceutical Market: Definition & Segmentation
Table 2 1: Global: Biopharmaceutical Market: SWOT Analysis
Table 2 2: Global: Recombinant Proteins Market Forecast: Sales by Class (in Million US$),
Table 2 3: Global: Monoclonal Antibodies Market Forecast: Sales by Class (In Million US$), 2011 & 2017
Table 2 4: Global: Purified Proteins Market Forecast: Sales by Class (In Million US$), 2011 & 2017
Table 2 5: Global: Biopharmaceutical Market Forecast: Sales by Region (In Million US$), 2012 & 2017
Table 3 1: Differences Between Small Molecule Drugs & Biopharmaceuticals
Table 3 2: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
Table 4 1: Global: Top Ten Selling Drugs (Based on Origin), 2000
Table 4 2: Global: Top Ten Selling Drugs (Based on Origin), 2011
Table 4 3: Global: Top Ten Selling Drugs Forecast (Based on Origin), 2016
Table 4 4: Mode of Administration of Popular Biotech Drugs
Table 4 5: FDA: Total Number of Biopharmaceutical Approvals in 2011
Table 4 6: US and European Statistics of Branded Biopharmaceutical Products Facing Biosimilar Threat (in Million US$), 2011
Table 5 1: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2005-2011
Table 5 2: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2012-2017
Table 5 3: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2011
Table 5 4: Global: Contribution of Various Classes to Total Biopharmaceutical Growth (in Million US$), 2011-2017
Table 5 5: Global: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 5 6: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 5 7: Global: Recombinant Proteins Market Forecast: Sales by Class (in %), 2012-2017
Table 5 8: Global: Recombinant Proteins Market Forecast: Sales Share by Class (in %), 2012-2017
Table 5 9: Global: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 5 10: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 5 11: Global: Monoclonal Antibodies Market Forecast: Sales by Class (in Million US$), 2012-2017
Table 5 12: Global: Monoclonal Antibodies Market Forecast: Sales Share by Class (in %), 2012-2017
Table 5 13: Global: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 5 14: Global: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 5 15: Global: Purified Proteins Market Forecast: Sales by Class (in Million US$), 2012-2017
Table 5 16: Global: Purified Proteins Market Forecast: Sales Share by Class (in %), 2012-2017
Table 5 17: Global: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 5 18: Global: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 5 19: Global: Biopharmaceutical Market Forecast: Sales of Top Biopharmaceuticals (in Million US$), 2011 & 2016
Table 6 1: US: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 6 2: US: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 6 3: US: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 6 4: US: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 6 5: US: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 6 6: US: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 6 7: US: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 6 8: US: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 6 9: Canada: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 6 10: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 6 11: Canada: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 6 12: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 6 13: Canada: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 6 14: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %) 2005-2011
Table 7 1: Mexico: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 7 2: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 7 3: Mexico: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 7 4: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 7 5: Mexico: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 7 6: Mexico: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 7 7: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 7 8: Brazil: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 7 9: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 7 10: Brazil: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 7 11: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 7 12: Brazil: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 7 13: Brazil: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 7 14: Brazil: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 7 15: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %) 2005-2011
Table 7 16: Argentina: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 7 17: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 7 18: Argentina: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 7 19: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 7 20: Argentina: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 7 21: Argentina: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 7 22: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 8 1: Germany: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 2: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 3: Germany: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 8 4: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 8 5: Germany: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 6: Germany: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 7: Germany: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 8 8: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 8 9: France: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 10: France: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 11: France: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 8 12: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 8 13: France: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 14: France: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 8 15: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 8 16: Italy: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 17: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 18: Italy: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 8 19: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 8 20: Italy: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 21: Italy: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 22: Italy: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 8 23: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %) 2005-2011
Table 8 24: Spain: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 25: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 26: Spain: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 8 27: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 8 28: Spain: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 29: Spain: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 30: Spain: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 8 31: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 8 32: UK: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 33: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 34: UK: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 8 35: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 8 36: UK: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 37: UK: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 38: UK: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 8 39: UK: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 8 40: Russia: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 41: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 42: Russia: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 8 43: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 8 44: Russia: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 45: Russia: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 46: Russia: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 8 47: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %) 2005-2011
Table 8 48: Turkey: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 49: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 8 50: Turkey: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 8 51: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 8 52: Turkey: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 8 53: Turkey: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 8 54: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %) 2005-2011
Table 9 1: Japan: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 2: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 3: Japan: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 9 4: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 9 5: Japan: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 6: Japan: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 7: Japan: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 9 8: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %) 2005-2011
Table 9 9: China: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 10: China: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 11: China: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 9 12: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 9 13: China: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 14: China: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 15: China: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 9 16: China: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 9 17: Australia: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 18: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 19: Australia: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 9 20: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 9 21: Australia: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 22: Australia: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 9 23: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %) 2005-2011
Table 9 24: South Korea: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 25: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 26: South Korea: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 9 27: South Korea: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 9 28: South Korea: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 29: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 30: South Korea: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 9 31: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %), 2005-2011
Table 9 32: India: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 33: India: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 34: India: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 9 35: India: Monoclonal Antibodies Market: Sales by Share (in %), 2005-2011
Table 9 36: India: Purified Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 37: India: Purified Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 38: India: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 9 39: India: Biopharmaceutical Market: Sales Share of Top Players (in %) 2005-2011
Table 9 40: Indonesia: Recombinant Proteins Market: Sales by Class (in Million US$), 2005-2011
Table 9 41: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2005-2011
Table 9 42: Indonesia: Monoclonal Antibodies Market: Sales by Class (in Million US$), 2005-2011
Table 9 43: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2005-2011
Table 9 44: Indonesia: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2005-2011
Table 9 45: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %) 2005-2011

Abstract

The global biopharmaceutical Industry has come a long way since its first drug - Humulin was approved in 1982. Today more than three hundred biopharmaceuticals have already been approved and many more are in late stages of clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases, but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s US$ 109 Billion figures and double digit growth rates in recent years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years. IMARC expects the global biopharmaceutical market to exceed sales worth US$ 166 Billion by 2017.

IMARC’s new report “Global Biopharmaceutical Market Report (2012-2017)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2017. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.

What We Have Achieved in this Report?

Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market

Key Aspects Analyzed:
  • Driving Factors
  • Restraining Factors
  • Market Opportunities
  • Threats
Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics
Regions/Countries Covered:
North America: United States and Canada
Latin America: Mexico, Brazil and Argentina
Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey
Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia

Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins

Focus of the Analysis for Each Country:
  • Total Market Performance (2005 - 2011)
  • Performance of Various Classes (2005 - 2011)
  • Performance of Top Players (2005 - 2011)
  • Market Forecast (2012 - 2017)
Key Questions Answered in this Report:
  • What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
  • What are the key opportunities and threats faced by the biopharmaceutical industry?
  • What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
  • Which are the world’s largest biopharmaceutical markets?
  • Which are the world’s fastest growing biopharmaceutical markets?
  • What is the structure and composition of various biopharmaceutical markets across the globe?
  • Which are the world’s largest biopharmaceutical segments?
  • Which are the world’s fastest growing biopharmaceutical segments?
  • Who are the world’s largest biopharmaceutical companies and how have they performed in recent years?


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.